A Phase 1 interventional study of Rozanolixizumab in Healthy Participants, sponsored by UCB Biopharma SRL. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to assess the concentration of rozanolixizumab in mature breast milk of healthy study participants following administration of a single dose of rozanolixizumab
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant and at least 1 of the following conditions applies:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants enrolled in this arm will receive a single dose of subcutaneous rozanolixizumab
Drug: Rozanolixizumab
Dose formulation: Solution for injection Route of administration: Subcutaneous infusion
Also known as: UCB7665
Concentration of Rozanolixizumab in Breast Milk Over a 7-day Sampling Period
The concentration of Rozanolixizumab in breast milk was calculated over the 7-day sampling period. Here, '\<=' denotes 'less than or equal to'; '\>' denotes 'greater than'; 'min' indicates minutes; and 'hrs' indicates hours.
Time frame: Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose
Estimated Daily Infant Dosage
The estimated daily infant dosage of Rozanolixizumab from breast milk was calculated based on the concentration of Rozanolixizumab in mature human breast milk. Estimated daily infant dosage (milligram per kilogram per day \[mg/kg/day\]) was equal to the milk-to-plasma ratio (M/P ratio) multiplied by the average maternal plasma concentration (Cav, plasma), and the standardized mean breastmilk intake by infant, which is 150 milliliters of breast milk per kilogram of infant body weight per day (150 mL/kg/day).
Time frame: Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose
Relative Infant Dose of Rozanolixizumab From Breast Milk
The relative infant dose of Rozanolixizumab from breast milk was calculated by dividing the estimated daily infant dosage (mg/kg/day) by maternal dosage (mg/kg/day) and then multiplying the result by 100.
Time frame: Predose (within 30 min) on Day 1 and at 0 to <=3, >3 to <=6, >6 to <=9, >9 to <=12, >12 to <=24, >24 to <=36, >36 to <=48, >48 to <=60, >60 to <=72, >72 to <=84, >84 to <=96, >96 to <=108, >108 to <=120, >120 to<=132, and >132 to<=144 hrs (Day 7) postdose
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A Treatment-emergent adverse events (TEAEs) were defined as any adverse events with a start date/time on or after dosing of the study medication and up to 8 weeks inclusive after dosing of the study medication. The participant data was rounded to one decimal place.
Time frame: From Day 1 Visit up to the Safety Follow-Up Visit (Day 57)
The study started to enroll participants in December 2024 and concluded in May 2025.
| Milestone | Rozanolixizumab |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
The concentration of Rozanolixizumab in breast milk was calculated over the 7-day sampling period. Here, '\<=' denotes 'less than or equal to'; '\>' denotes 'greater than'; 'min' indicates minutes; and 'hrs' indicates hours.
| micrograms per milliter (ug/mL) | Rozanolixizumab |
|---|---|
| Predose (Day 1) | NA ± NA |
| 0 to <=3 hours postdose (Day 1) | NA ± NA |
| >3 to <=6 hours postdose (Day 1) | NA ± NA |
| >6 to <=9 hours postdose (Day 1) | NA ± NA |
| >9 to <=12 hours postdose (Day 1) | NA ± NA |
| >12 to <=24 hours postdose (Day 1) | NA ± NA |
| >24 to <=36 hours postdose (Day 2) | NA ± NA |
| >36 to <=48 hours postdose (Day 2) | NA ± NA |
| >48 to <=60 hours postdose (Day 3) | NA ± NA |
| >60 to <=72 hours postdose (Day 3) | NA ± NA |
| >72 to <=84 hours postdose (Day 4) | NA ± NA |
| >84 to <=96 hours postdose (Day 4) | NA ± NA |
| >96 to <=108 hours postdose (Day 5) | NA ± NA |
| >108 to <=120 hours postdose (Day 5) | NA ± NA |
| >120 to <=132 hours postdose (Day 6) | NA ± NA |
| >132 to <=144 hours postdose (Day 7) | NA ± NA |
The estimated daily infant dosage of Rozanolixizumab from breast milk was calculated based on the concentration of Rozanolixizumab in mature human breast milk. Estimated daily infant dosage (milligram per kilogram per day \[mg/kg/day\]) was equal to the milk-to-plasma ratio (M/P ratio) multiplied by the average maternal plasma concentration (Cav, plasma), and the standardized mean breastmilk intake by infant, which is 150 milliliters of breast milk per kilogram of infant body weight per day (150 mL/kg/day).
No measurements were reported for this outcome.
The relative infant dose of Rozanolixizumab from breast milk was calculated by dividing the estimated daily infant dosage (mg/kg/day) by maternal dosage (mg/kg/day) and then multiplying the result by 100.
No measurements were reported for this outcome.
An Adverse Event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. A Treatment-emergent adverse events (TEAEs) were defined as any adverse events with a start date/time on or after dosing of the study medication and up to 8 weeks inclusive after dosing of the study medication. The participant data was rounded to one decimal place.
| percentage of participants | Rozanolixizumab |
|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 73.3 |
Collected over From Day 1 Visit up to the Safety Follow-Up Visit (Day 57). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rozanolixizumab | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| Event | Rozanolixizumab |
|---|---|
| HeadacheNervous system disorders | 9/15 |
| Upper respiratory tract infectionInfections and infestations | 3/15 |
| MastitisInfections and infestations | 2/15 |
| NauseaGastrointestinal disorders | 1/15 |
| VomitingGastrointestinal disorders | 1/15 |
| Injection site haemorrhageGeneral disorders | 1/15 |
| Vulvovaginal candidiasisInfections and infestations | 1/15 |
| Breast milk discolourationReproductive system and breast disorders | 1/15 |
| UrticariaSkin and subcutaneous tissue disorders | 1/15 |
The SS included all study participants who received a full or partial dose of the investigational medicinal product (IMP).
| Age, Continuous(years) | Rozanolixizumab |
|---|---|
| Mean | 30.5 ± 4.6 |
| Age, Customized(Participants) | Rozanolixizumab |
|---|---|
| 18 - <65 years | 15 |
| 65 - <85 years | 0 |
| >= 85 years | 0 |
| Sex: Female, Male(Participants) | Rozanolixizumab |
|---|---|
| Female | 15 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | Rozanolixizumab |
|---|---|
| Race — Black | 1 |
| Race — White | 14 |
| Race/Ethnicity, Customized(Participants) | Rozanolixizumab |
|---|---|
| Ethnicity — Hispanic or Latino | 3 |
| Ethnicity — Not Hispanic or Latino | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Due to the small sample size in this trial, individual participant-level data cannot be adequately anonymized as there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.
Ran from Dec 2024 to primary completion in May 2025, 5 months.
Results were first posted in Jun 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab